4841 - 4850 of 8801 Results
Title
Year
-
RESTRICTEDTitle: Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trialJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 12Start Page: 1099End Page: 1109Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00400-8Citation Count: 145
-
RESTRICTEDTitle: Major advances in Parkinson's disease over the past two decades and future research directionsJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 12Start Page: 1076End Page: 1079Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00448-3Citation Count: 13
-
RESTRICTEDTitle: Inconsistency and incongruence: the two diagnostic pillars of functional movement disorderJournal Name: The LancetPublisher: Elsevier BVVol: 400Issue #: 10348Start Page: 328End Page: 328Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s0140-6736(22)01184-9Citation Count: 7
-
RESTRICTEDTitle: Mild and direct 18F radiofluorination of tetrazines through sulfonium salt precursorsJournal Name: Nuclear Medicine and BiologyPublisher: Elsevier BVVol: 108-109Issue #:Start Page: S88End Page: S89Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s0969-8051(22)00209-8Citation Count: 0
-
RESTRICTEDTitle: Optimizing the reaction conditions for the GMP production of [18F]ACI-12589, a promising candidate in the development as a PET tracer targeting α-synucleinJournal Name: Nuclear Medicine and BiologyPublisher: Elsevier BVVol: 108-109Issue #:Start Page: S87End Page: S88Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s0969-8051(22)00207-4Citation Count: 0
-
OPENTitle: Prehospital scales in acute ischaemic stroke management – Authors' replyJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 20Issue #: 7Start Page: 504End Page: 505Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00169-1Best OA location URL: https://pure.eur.nl/en/publications/25abb6f2-0472-4754-8580-97e2533ac37aCitation Count: 1
-
OPENTitle: Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trialJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 20Issue #: 3Start Page: 182End Page: 192Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(20)30489-0Best OA location URL: http://www.thelancet.com/article/S1474442220304890/pdfCitation Count: 117
-
OPENTitle: The GBA-370Rec Parkinson's disease risk haplotype harbors a potentially pathogenic variant in the mitochondrial gene SLC25A44Journal Name: Molecular Genetics and MetabolismPublisher: Elsevier BVVol: 133Issue #: 1Start Page: 109End Page: 112Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.ymgme.2021.03.012Citation Count: 3
-
OPENTitle: Adapting the proteostasis capacity to sustain brain healthspanJournal Name: CellPublisher: Elsevier BVVol: 184Issue #: 6Start Page: 1545End Page: 1560Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.cell.2021.02.007Best OA location URL: http://www.cell.com/article/S0092867421001574/pdfCitation Count: 108
-
OPENTitle: Home-based transcranial static magnetic field stimulation of the motor cortex for treating levodopa-induced dyskinesias in Parkinson's disease: A randomized controlled trialJournal Name: Brain StimulationPublisher: Elsevier BVVol: 15Issue #: 3Start Page: 857End Page: 860Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.brs.2022.05.012Best OA location URL: http://www.brainstimjrnl.com/article/S1935861X22000912/pdfCitation Count: 19